Second of two multi-center trial of IMO-2125 as monotherapy and in combination with check-point inhibitors in multiple tumor types.

Trial Profile

Second of two multi-center trial of IMO-2125 as monotherapy and in combination with check-point inhibitors in multiple tumor types.

Planning
Phase of Trial: Phase II

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs IMO 2125 (Primary)
  • Indications Tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2016 New trial record
    • 28 Oct 2016 According to an Idera Pharmaceuticals media release, company plans to initiate this trial in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top